| Identification | Back Directory | [Name]
1-METHYLADENOSINE | [CAS]
15763-06-1 | [Synonyms]
1-METHYLADENOSINE
Adenosine, 1-methyl-
1-methyladenosine free base
N,6-Didehydro-1,6-dihydro-1-methyladenosine
(2R,3R,4R,5R)-2-(hydroxymethyl)-5-(6-imino-1-methyl-purin-9-yl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-(6-Amino-1-methyl-1H-purin-9(2H)-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol | [Molecular Formula]
C11H15N5O4 | [MDL Number]
MFCD00038421 | [MOL File]
15763-06-1.mol | [Molecular Weight]
281.27 |
| Chemical Properties | Back Directory | [Melting point ]
>217°C (dec.) | [Boiling point ]
655.4±65.0 °C(Predicted) | [density ]
1.88±0.1 g/cm3(Predicted) | [storage temp. ]
−20°C | [solubility ]
DMSO (Slightly), Water (Slightly, Sonicated) | [form ]
Solid | [pka]
13.24±0.70(Predicted) | [color ]
White to Off-White | [PH]
8.8 | [λmax]
258 (pH 2)；258 (pH 7)；259，260～265 (pH 13) | [Stability:]
Hygroscopic, Light Sensitive | [InChI]
InChI=1/C11H15N5O4/c1-15-3-14-10-6(9(15)12)13-4-16(10)11-8(19)7(18)5(2-17)20-11/h3-5,7-8,11-12,17-19H,2H2,1H3/t5-,7-,8-,11-/s3 | [InChIKey]
GFYLSDSUCHVORB-ABFAXUGDNA-N | [SMILES]
N1(C=NC2C(=N)N(C)C=NC1=2)[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 |&1:11,12,14,16,r| |
| Hazard Information | Back Directory | [Description]
1-Methyladenosine is a modified nucleoside generated by the processing of tRNA by methyltransferases.1,2,3 The urinary excretion of 1-methyladenosine is elevated in several forms of cancer, supporting its use as a biomarker in early detection.4,5,6 It can also be monitored in serum.7 Urinary levels of 1-methyladenosine also increase during active rheumatoid arthritis.8 | [Chemical Properties]
White to off-white crystalline powder | [Uses]
1-Methyl Adenosine is a modified adenosine molecule created through the processing of tRNA by methyltransferases. The presence seen to be elevated in the urinary excretion of cancer patients. Thus it may be an early diagnosis biomarker. | [Definition]
ChEBI: A methyladenosine carrying a methyl substituent at position 1. | [References]
[1] T. MUNNS H S. Methylation and processing of transfer ribonucleic acid in mammalian and bacterial cells.[J]. The Journal of Biological Chemistry, 1975, 4 1: 2143-2149. DOI: 10.1016/s0021-9258(19)41693-1
[2] VOLD B. Modified nucleosides of Bacillus subtilis transfer ribonucleic acids.[J]. Journal of Bacteriology, 1976, 127 1: 258-267. DOI: 10.1128/jb.127.1.258-267.1976
[3] TAKESHI CHUJO Tsutomu S. Trmt61B is a methyltransferase responsible for 1-methyladenosine at position 58 of human mitochondrial tRNAs.[J]. RNA, 2012, 18 12: 2269-2276. DOI: 10.1261/rna.035600.112
[4] C. REYNAUD . Monitoring of urinary excretion of modified nucleosides in cancer patients using a set of six monoclonal antibodies[J]. Cancer letters, 1992, 61 3: Pages 255-262. DOI: 10.1016/0304-3835(92)90296-8
[5] A SEIDEL. Modified nucleosides: an accurate tumour marker for clinical diagnosis of cancer, early detection and therapy control[J]. British Journal of Cancer, 2006, 94 11: 1726-1733. DOI: 10.1038/sj.bjc.6603164
[6] WEI-YI HSU. Urinary nucleosides as biomarkers of breast, colon, lung, and gastric cancer in Taiwanese.[J]. PLoS ONE, 2013: e81701. DOI: 10.1371/journal.pone.0081701
[7] FENG CHEN. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method[J]. Analytical and Bioanalytical Chemistry, 2011, 401 6. DOI: 10.1007/s00216-011-5245-3
[8] J G TEBIB. Relationship between urinary excretion of modified nucleosides and rheumatoid arthritis process.[J]. British journal of rheumatology, 1997, 36 9: 990-995. DOI: 10.1093/rheumatology/36.9.990 |
|
|